Discloses the use of an engineered single-stranded oligonucleotide in the manufacture of a medicament for preventing or treating pathologic cardiac hypertrophy, heart failure, or myocardial infarction. The disclosed oligonucleotide is a modified small interfering RNA molecule that is complementary to a portion of gene sequence miR-208.